GLSI Greenwich LifeSciences Inc
Price (delayed)
$9.35
Market cap
$122.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.8
Enterprise value
$117.08M
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a
Highlights
The quick ratio has plunged by 78% YoY but it is up by 29% from the previous quarter
The equity fell by 44% YoY and by 15% QoQ
The net income has contracted by 17% YoY and by 2.7% from the previous quarter
Key stats
What are the main financial stats of GLSI
Market
Valuations
Earnings
Shares outstanding
13.14M
Market cap
$122.9M
Enterprise value
$117.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
24.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$10.76M
Net income
-$10.5M
EBIT
-$10.5M
EBITDA
-$10.49M
Free cash flow
-$7.57M
Per share
Balance sheet
Liquidity
EPS
-$0.8
EPS diluted
-$0.8
Free cash flow per share
-$0.58
Book value per share
$0.38
Revenue per share
$0
TBVPS
$0.44
Total assets
$5.83M
Total liabilities
$842,384
Debt
$0
Equity
$4.98M
Working capital
$4.98M
Debt to equity
0
Current ratio
6.91
Quick ratio
6.91
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-164.3%
Return on equity
-185.1%
Return on invested capital
N/A
Return on capital employed
-210.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLSI stock price
How has the Greenwich LifeSciences stock price performed over time
Intraday
0.97%
1 week
-12.04%
1 month
-23.49%
1 year
-46.54%
YTD
-16.74%
QTD
-1.99%
Financial performance
How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.76M
Net income
-$10.5M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 17% YoY and by 2.7% from the previous quarter
The operating income has declined by 15% year-on-year and by 2.1% since the previous quarter
Growth
What is Greenwich LifeSciences's growth rate over time
Valuation
What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
24.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is down by 13% year-on-year
The equity fell by 44% YoY and by 15% QoQ
GLSI's P/B is 33% lower than its last 4 quarters average of 36.5 but 30% higher than its 5-year quarterly average of 18.8
Efficiency
How efficient is Greenwich LifeSciences business performance
The return on equity has dropped by 130% year-on-year and by 20% since the previous quarter
The ROA has shrunk by 109% YoY and by 16% QoQ
Dividends
What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLSI.
Financial health
How did Greenwich LifeSciences financials performed over time
The company's total liabilities has surged by 183% YoY but it fell by 38% QoQ
The current ratio has plunged by 78% YoY but it has increased by 29% from the previous quarter
The company's debt is 100% lower than its equity
The equity fell by 44% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.